Market Pulse: Stocks drifted under mixed earnings signals, futures edging higher into a quiet morning.
Key Movers: UnitedHealth flexed on Q3 results to lift sentiment, while ASML warned supply constraints as AI demand surges—momentum in health-care insurers and chip equipment stocks.
Macro & Politics: The FDA quietly expanded GORE® VIABAHN® VBX’s label for vascular repairs, potentially catalyzing device M&A chatter.
What’s Next: Eyes on Fed speakers and any earnings whispers from financials ahead of today’s open.
📈 Breaking Financial News
UnitedHealth Earnings Beat Wall Street Estimates. The Turnaround Continues. – Barron's
UnitedHealth Earnings Beat Wall Street Estimates. The Turnaround Continues.Barron's UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costsCNBC UnitedHealth posts $4B profit in comeback from financial spiralStar Tribune U…
UnitedHealth Group raises profit forecast on third-quarter earnings beat – Yahoo Finance
UnitedHealth Group raises profit forecast on third-quarter earnings beatYahoo Finance UnitedHealth Group tops estimates, hikes profit outlook as insurer manages high medical costsCNBC UnitedHealth raises profit forecast again as turnaround efforts gather pace…
UnitedHealth Group raises profit forecast on third-quarter earnings beat
By Amina Niasse
NEW YORK, Oct 13 (Reuters) – UnitedHealth Group (UNH) on Tuesday raised its 2026 profit forecast as the company tightened spending on medical costs in its health insurance business and improved margins in its Optum clinical care and health tec…
Cocaine Use Disorder Market Outlook to Strengthen During the Forecast Period (2026-2036) with Emerging Therapies and Rising Healthcare Needs | DelveInsight
The cocaine use disorder market is expected to be driven by the anticipated introduction of emerging therapies including Mavoglurant (STP7; STALICLA), Metyrapone (EMB-001; Embera NeuroTherapeutics), TMP-301 (Tempero Bio), OMS527 (Omeros Corporation), AT-312 (…
Cocaine Use Disorder Market Outlook to Strengthen During the Forecast Period (2026-2036) with Emerging Therapies and Rising Healthcare Needs | DelveInsight
The cocaine use disorder market is expected to be driven by the anticipated introduction of emerging therapies including Mavoglurant (STP7; STALICLA), Metyrapone (EMB-001; Embera NeuroTherapeutics), TMP-301 (Tempero Bio), OMS527 (Omeros Corporation), AT-312 (…
Elon Musk says universal income is coming. Robert Kiyosaki says one version already exists.
Kiyosaki calls it the Patriot Income Plan: an income play funded entirely by America's oil and gas infrastructure, paying 10% a year across 42 separate payments to everyone who owns units.
🔍 Market Analysis & Insights
FDA APPROVES GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS FOR EXPANDED USE IN FEVAR AND BEVAR
Approval brings U.S. vascular surgeons the first on-label bridging stent graft for both fenestrated and branched endovascular aortic repair, as three-year clinical outcomes demonstrate safety and effectiveness. FLAGSTAFF, Ariz., Oct. 14, 2026 /PRNewswire/ — …
Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
SAN DIEGO, Oct. 14, 2026 /PRNewswire/ — Equity Insider News Commentary – Global spending on cancer medicines reached $252 billion in 2024 and is forecast to exceed $400 billion by 2028, according to the IQVIA Institute, with the United States accounting for …
Chip tool giant ASML nudges up outlook as AI-driven demand outruns supply
Oct 14 : ASML said on Wednesday that AI-driven demand for its chip-printing tools is so strong that it will not be able to fully meet customer demand in 2027 or 2028 and that it is looking at ways to expand capacity as it raised its full-year sales outlook.Th…
JPMorgan records rare earnings miss, Goldman Sachs delivers blowout revenue in mixed quarter
JPMorgan – the largest US bank by assets and the largest in the world by market cap – reported earnings per share of $5.57, missing estimates of $5.90. It recorded revenue of $50.91 billion, below expectations of $51.22 billion.
Wells Fargo beats profit estimates, NII and revenue fall short
Wells Fargo beats profit estimates, NII and revenue fall shorttheglobeandmail.com
Missed the AI Boom? This $20 Stock Could Be Bigger
My readers saw gains as high as 502% on my past AI picks. But the next one? It could be even bigger. Warren Buffett owns $40B in this sector. Elon Musk says it's essential for civilization.
💰 Investment Opportunities
Some peptide users report lasting symptoms as RFK Jr. pushes for wider access
After the third day of squirting an experimental drug up his nose, Dylan Meetze felt horrible.”It was like I was underwater, like it took the most to do anything,” he said.Subscribe to The Post Most newsletter for the most important and interesting stories fr…
Rebecca Solnit's (Mis)Adventures in the Manosphere
Rebecca Solnit explores an America where the right has turned hatred of women into an ever-expanding, multi-platform Internet grift.
The post Rebecca Solnit's (Mis)Adventures in the Manosphere appeared first on The Nation.
People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA’s Push for Medical Freedom.
People who have taken experimental peptides, such as BPC-157, complain of migraines, eye pain, fatigue, and more. Learning whether these popular but unproven drugs are to blame may become harder if Robert F. Kennedy Jr. fulfills a promise to make them more ac…
Psychedelic medicine is approaching a turning point. The U.S. needs the right infrastructure to be ready
Today’s psychedelics bear little resemblance to 1970s counterparts. These medicines undergo rigorous clinical trials and licensed manufacturing processes.
Accord BioPharma Launches FILKRI™ (filgrastim-laha); Now Offers Both Long- and Short-Acting G-CSF Options
FILKRI is available with a permanent Q-code, standardizing the billing and reimbursement process across all sites of care. RALEIGH, N.C., Oct. 12, 2026 /PRNewswire/ — Accord BioPharma, Inc., the specialty division of Intas Pharmaceuticals, Ltd., focused on t…
A Coin At Half A Penny Only Needs To Move A Cent And A Half To Gain 300%
That's the quiet math behind micro coins: money that barely nudges Bitcoin can multiply a coin worth a few million. Crypto 101's Bryce Paul shows how he finds them and decides which are worth the risk. Most never do anything; investing carries risk.
Everyone’s too fixated on headline beats from UnitedHealth Group (“UnitedHealth Group raises profit forecast on third-quarter earnings beat” – Yahoo Finance) without sizing up creeping medical-cost pressure in its Optum arm. Lifting guidance placates bulls, but the real risk is margin sputter if health-care inflation spikes again—something brokers rarely stress when chasing a quarter-over-quarter beat.
Likewise, the chip narrative from ASML (“Chip tool giant ASML nudges up outlook as AI-driven demand outruns supply” – CNA) seems worlds apart from the FDA’s under-the-radar blessing of GORE® VIABAHN® VBX (PRNewswire). Yet both stories hinge on capacity: one in silicon fab lines, the other in clinical-trial throughput. If production bottlenecks govern returns in semis and med-dev alike, you’re overlooking parallel plays that could deliver outsized gains.
Action time: load up on names with tangible catalysts—UnitedHealth and ASML lead the pack, but don’t sleep on device specialists benefiting from regulatory nods. Trim positions in overhyped sectors, and redeploy into areas where you can see the demand curve, not just hear it whispered by consensus bulls.